Även om Cell impacts utveckling går långsammare än vi tidigare prognosticerat bedömer vi att Cell Im...
Redeye views favorably the announcement of the first order from the US Department of Veterans Affair...
Kvällen den 27 augusti offentliggjorde edyoutec sin delårsrapport för kv2 2024.
Embark Group AB (”Embark” eller ”Bolaget”) fortsatte under det andra kvartalet att kapitalisera på t...
Nettoomsättningen i det andra kvartalet uppgick till 202,7 MSEK (203,9), en minskning med cirka 0,6 ...
Q2 EBITDA 1% below cons on Sportsbook and Platform miss Decent start to Q3 with Media sales up 37% y...
Redeye comments on GiG’s Q2 results, which were overall close to our forecast although Media was str...
Q2: 21% ARR growth in line, FCF of DKK -4m vs. ABGSCe DKK -6m Reiterates FY'24 guidance, as expected...
Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher ...
Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was ...
After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of ...
Redeye makes mixed estimate revisions on the back of Nekkar’s H1’24 report that beat our EPS forecas...
Weak Q2 margin of 5.0% (7.3%), but book-to-bill improved to 0.
Genom marknadsföringssatsningar, registrerat JV i Kina, ett breddat distributionsnätverk samt godkän...
Mendus’s Q224 results reflect a period of steady progress across its clinical programmes.
Market headwinds continued in Q2 We lower 2025e EBIT on slower recovery in activity Easy comps in '2...
Redeye leaves a comment relating to the announcement of Werfen and its new POC system GEM Premier 70...
XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) har i slutet av juni passerat f...
Under kv2 2024 levererade Fable Media en nettoomsättning i linje med vår förväntan.
The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with ...
